Last reviewed · How we verify

Tezacaftor/Ivacaftor — Competitive Intelligence Brief

Tezacaftor/Ivacaftor (Tezacaftor/Ivacaftor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR modulator (corrector + potentiator combination). Area: Pulmonary/Respiratory.

phase 3 CFTR modulator (corrector + potentiator combination) CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Pulmonary/Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Tezacaftor/Ivacaftor (Tezacaftor/Ivacaftor) — Vertex Pharmaceuticals Incorporated. Tezacaftor is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly, while ivacaftor is a CFTR potentiator that increases the channel-opening probability of CFTR at the cell surface.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tezacaftor/Ivacaftor TARGET Tezacaftor/Ivacaftor Vertex Pharmaceuticals Incorporated phase 3 CFTR modulator (corrector + potentiator combination) CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CFTR modulator (corrector + potentiator combination) class)

  1. Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tezacaftor/Ivacaftor — Competitive Intelligence Brief. https://druglandscape.com/ci/tezacaftor-ivacaftor. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: